The long-acting medication octreotide mimics the pharmacologic actions of the somatostatin hormone, which blocks the release of growth hormone. 8 Acromegaly and symptoms brought on by various cancers, such as carcinoid tumours and vasoactive intestinal tumours, are also treated with it (VIPomas). 8 In the past, injections were the only way to give Octreotide. On June 26, 2020, the FDA authorised Mycapssa, the first approved delayed-release oral somatostatin analogue, for the long-term maintenance therapy of acromegaly. Chiasma Inc. created this medication.
Side effects of Octreotide-
· The majority of people do not experience all of the listed negative effects.
· When it comes to their onset and length, side effects are frequently predictable.
· Almost always, after therapy is over, side symptoms are curable and disappear.
· There are numerous ways to lessen or avoid negative effects.
· The presence or intensity of a medication's adverse effects has no bearing on how well it works.
· The dosage of the medication and the preparation (Sandostatin® or Sandostatin LAR®) used determine the side effects of octreotide and the severity of such side effects. To put it another way, larger doses could result in more severe adverse effects.
Read More- https://coherentmarketinsightsus.blogspot.com/2023/02/a-somatostatin-like-octapeptide.html
